Myeloproliferative neoplasms are associated with lymphoproliferative diseases following the administration of cytotoxic drugs or exposure to radiation, but are rare prior to therapy. The present study reports the case of a 61-year-old female with a history of transient ischemic attack. The patient, who presented with a palpable mass in the epitrochlear area of the left arm, was simultaneously diagnosed with follicular lymphoma and an unclassifiable myeloproliferative neoplasm. Excisional lymph node biopsy revealed stage I follicular lymphoma (grade 1). Laboratory findings demonstrated leukocytosis, erythrocytosis, thrombocytosis and decreased erythropoietin. Biopsy of the bone marrow revealed hypercellularity, with predominance of erythroid cells, and large polylobated megakaryocytes with increased mitotic figures, but no evidence of lymphomatous infiltration. The janus kinase 2 V617F mutation was also detected in the cells derived from the bone marrow specimen. Following local excision of the lymph node in the left epitrochlear area, radiation was delivered to the involved field, at a dose of 24 Gy in 12 fractions. The patient was started on hydroxyurea (1 g twice per day, orally) 2 weeks subsequent to radiotherapy, and was administered 500 mg twice per day as maintenance therapy. At the six-month follow-up, the white blood cell count, hemoglobin levels and platelet count had reduced, and the patient was in a healthy condition. A computed tomography scan of the neck, chest and abdomen indicated no abnormalities. To the best of our knowledge, the present study is the first case report of follicular lymphoma coexisting with an unclassifiable myeloproliferative neoplasm in a previously healthy patient. Molecular and genetic studies are required to further evaluate this infrequent disease association.
Introduction
Follicular lymphoma is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells (1) . Patients with follicular lymphoma present with diffuse lymphadenopathy, bone marrow involvement and splenomegaly; in rare cases, other extranodal sites may also be involved (1) . Follicular lymphoma is one of the most common subtypes of non-Hodgkin lymphoma (NHL) with an estimated incidence of 3.18 cases per 100,000 individuals in the USA (2) . Follicular lymphoma is the initial neoplasm for indolent lymphomas and has a median overall survival of >10 years (1) . Observation or radiation therapy is adequate for asymptomatic and low tumor bulk disease cases (3, 4) . For patients needing therapy, the majority of patients are treated with chemotherapy plus rituximab (5) (6) (7) .
Myeloproliferative neoplasms are characterized by terminal myeloid cell expansion in the peripheral blood, resulting in various combinations of erythrocytosis, leukocytosis, thrombocytosis, bone marrow hypercellularity/fibrosis and splenomegaly (8) . Polycythemia vera is a Philadelphia-negative myeloproliferative disease associated with JAK2 mutation characterized by erythrocytosis; patients are treated by phlebotomy and/or cytotoxic drugs (9) . Myeloproliferative neoplasms are associated with lymphoproliferative disease following the administration of cytotoxic drugs or exposure to radiation, but are rarely observed prior to therapy (10, 11) .
In the present study, a case of a 61-year-old female with a history of transient ischemic attack is reported. The patient was simultaneously diagnosed with follicular lymphoma and an unclassifiable myeloproliferative neoplasm. It is possible that the coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm prior to the administration of a cytotoxic drug or exposure to radiation may involve 2 unrelated clones of different lineages. 
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metabolism of the skeletal bone marrow was also observed throughout the body. A biopsy of the bone marrow revealed hypercellularity, with predominance of cells derived from the erythroid series and large polylobated megakaryocytes with increased mitotic figures. However, no evidence of lymphomatous infiltration was observed (Fig. 2) . The V617F mutation in janus kinase 2 (JAK2) was also detected in the cells of the bone marrow specimen. Based on these results, the disease was considered to be at a clinical stage I, and the follicular lymphoma international prognostic index score indicated an intermediate risk (12) . Following local excision of the lymph node, radiation was delivered to the involved field at a dose of 24 Gy in 12 fractions. A computed tomography scan of the neck, chest and abdomen performed 3 months later revealed no abnormalities. Following phlebotomy and plasma apheresis, the patient was started on hydroxyurea (1 g twice per day, orally) 2 weeks subsequent to the end of radiotherapy, and was administered 500 mg twice per day of the drug as maintenance therapy. On the sixth month of follow-up, the WBC count, hemoglobin, hematocrit and platelet count were reduced to 7,430 cells/µl, 12.2 g/dl, 36.5% and 379,000 cells/µl, respectively, and the patient was in a healthy condition at the time of reporting.
Discussion
A small number of patients (<10%) diagnosed with follicular lymphoma present stage I/II of the disease (13). In these 
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cases, radiation therapy is the treatment of choice, following which, the 10-year overall survival rate is 60-80%, with a median survival time of ~19 years (3). The therapies for polycythemia vera are aimed at preventing the occurrence of thrombosis (19, 20) . The initial therapy for patients at high risk of developing thrombosis consists of phlebotomy plus a low dose of aspirin, supplemented with a cytoreductive agent, such as hydroxyurea (21) . In the present report, radiation was delivered to the involved field, following local excision of the lymph node in the left epitrochlear area. The patient was administered hydroxyurea and aspirin subsequent to phlebotomy and plasma apheresis. Direct or indirect dysregulation of the tyrosine kinase JAK2 signaling pathway, as a result of somatically acquired mutations, is involved in the pathogenesis of myeloproliferative neoplasms (22) . JAK2 participates in the signaling pathways initiated by the cytokine receptors that are required for normal myelopoiesis, including those for erythropoietin, thrombopoietin and granulocyte colony stimulating factor (23) . The JAK2 V617F variant increases genomic instability by reducing apoptosis secondary to DNA damage, and by altering the expression of a number of genes, which in turn may increase the risk of genetic lesions that lead to leukemic transformation (24) .
The JAK2 V617F mutation is present in 95% of patients with polycythemia vera and in ~50% of patients with primary myelofibrosis or essential thrombocythemia (24, 25) . This mutation has also been observed in patients affected by other myeloid diseases, including 67% of patients with refractory anemias and ring sideroblasts associated with thrombocytosis (26), 7.8% of patients with chronic myelomonocytic leukemias and a low percentage of patients with primary acute myeloblastic leukemias, myelodysplastic syndromes and chronic myeloid leukemia (27) . However, to the best of our knowledge, the JAK2 V617F mutation has not been detected in follicular lymphoma thus far. Furthermore, the coexistence of follicular lymphoma and myeloproliferative neoplasm is rare (14, 28) .
There are limited number of reports in the literature that are relevant to the case described in the present report (Table I) . It is uncertain whether there is a pathogenetic association between the myeloproliferative and lymphoproliferative diseases: It is likely that both are as a result of random mutations occurring in distinct initiating cells. However, given the higher risk of lymphoproliferative neoplasms development in myeloproliferative neoplasms reported in larger studies, the genomic instability characteristic to myeloproliferative neoplasms may contribute to subsequent lymphoproliferative neoplasms occurrence (29, 30) . The pathogenesis may be attributed to reduced immunocompetence and/or anti oncogene suppression.
In the present study, the JAK2 V617F mutation was identified in the malignant cells of a patient with an unclassifiable myeloproliferative neoplasm and coexisting follicular lymphoma. This finding may indicate that the JAK2 V617F mutation represents a secondary event to primary gene mutations in the primitive stem cells, which leads to the development of a follicular lymphoma and an unclassifiable myeloproliferative neoplasm. Regardless, further studies using molecular and genetic approaches may aid in the understanding of this rare occurrence of neoplasms.
